Skip to content

Dr. Reddy's Laboratories

US · RDY #1451 by market cap Listed 1970
14.89 +0.06 +0.40%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Recent news

  • Company notice
    Dr. Reddy's Laboratories | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
    SEC · 2026/11/11
  • Company notice
    Dr. Reddy's Laboratories | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
    SEC · 2026/10/30
  • Tonix Pharmaceuticals Files Patent Infringement Complaint Against Dr. Reddy's Laboratories On Nov 13, 2026; Seeks To Delay FDA Approval Of Dr. Reddy's Laboratories Anda Until Patent Expiration; Triggers Statutory Stay Of FDA Approval Of Dr. Reddy's...
    Benzinga · 2026/11/14
  • Rating change
    BNP Paribas Initiates Dr. Reddy's Laboratories(RDY.US) With Buy Rating, Announces Target Price $14.8
    Market Newswire · 2026/10/12
  • Rating change
    BNP Paribas Upgrades Dr. Reddy's Laboratories to Outperform Neutral, $14.80 Price Target
    MT Newswires · 2026/10/12
  • Rating change
    Citigroup Upgrades Dr Reddy's Laboratories to Buy, Raises Price Target to $1450
    Benzinga · 2026/9/30
  • Jefferies Upgrades Dr. Reddy's Laboratories to Hold From Sell, Price Target Is $13.90
    MT Newswires · 2026/10/26
  • Company notice
    Dr. Reddy's Laboratories | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
    SEC · 2026/11/5
  • Rating change
    Shaw and Partners Keeps Their Buy Rating on ReadyTech Holdings Ltd. (RDY)
    TipRanks · 2026/8/31
  • Rating change
    Jefferies Initiates Dr. Reddy's Laboratories(RDY.US) With Hold Rating, Announces Target Price $13.89
    Market Newswire · 2026/10/26
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Zentek (OtherZTEKF) and Dr Reddy's Laboratories (RDY)
    TipRanks · 2026/10/1
  • Rating change
    Morgans Sticks to Its Buy Rating for ReadyTech Holdings Ltd. (RDY)
    TipRanks · 2026/9/1
  • Company notice
    Dr. Reddy's Laboratories | 144: Notice of proposed sale of securities pursuant to Rule 144
    SEC · 2026/11/3
  • BofA Securities Maintains Dr. Reddy's Laboratories(RDY.US) With Buy Rating
    Market Newswire · 2026/10/26
  • Form 144 | Dr. Reddy's Laboratories(RDY.US) Insider Proposes to Sell 6.54 Million in Common Stocks
    Market Newswire · 2026/11/3
  • Rating change
    Elara Securities India Downgrades Dr. Reddy's Laboratories to Reduce From Accumulate; Price Target Is INR1,283
    MT Newswires · 2026/7/10
  • Rating change
    Jarden Remains a Buy on ReadyTech Holdings Ltd. (RDY)
    TipRanks · 2026/9/1
  • Dr. Reddy's Laboratories | 6-K: Report of foreign private issuer (related to financial reporting)
    SEC · 2026/10/26
  • Rating change
    Nomura Adjusts Dr. Reddy's Laboratories' Price Target to INR1,740 From INR1,600, Keeps at Buy
    MT Newswires · 2026/6/22
  • Company notice
    Dr. Reddy's Laboratories | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
    SEC · 2026/11/4
  • Company notice
    Dr. Reddy's Laboratories | 6-K: Report of foreign private issuer (related to financial reporting)
    SEC · 2026/10/24
  • Company notice
    Dr. Reddy's Laboratories | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
    SEC · 2026/10/26
  • Rating change
    BofA Securities Maintains Dr. Reddy's Laboratories(RDY.US) With Buy Rating, Cuts Target Price to $16.33
    Market Newswire · 2026/6/18
  • Dr Reddy's Laboratories Q2 2027 Earnings Call Transcript
    Benzinga · 2026/10/23
  • Company notice
    Dr. Reddy's Laboratories | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
    SEC · 2026/10/29

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 20:02:31 · For reference only, not investment advice and not tailored to your situation.

Dr. Reddy's Laboratories discussion 0 comments

Add a comment